Abstract: The invention relates to compositions and methods for inhibiting Krüppel-like Factor 10 (KLF10) for modulation of T regulatory cells and cancer immunotherapy.
Type:
Application
Filed:
January 28, 2022
Publication date:
June 16, 2022
Applicants:
The Brigham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.
Abstract: The present invention relates to methods of treating patients with advanced forms of cancer, such as clear cell renal cell carcinoma, in which X4P-001 is administered in order to reduce angiogenic escape that typically occurs with TKI therapy. The methods demonstrate surprising results, including regression of tumor size and cell number, with comparatively little toxicity.
Type:
Grant
Filed:
December 14, 2016
Date of Patent:
June 14, 2022
Assignees:
X4 Pharmaceuticals, Inc., Georgetown University, Beth Israel Deaconess Medical Center, Inc.
Inventors:
Robert D. Arbeit, Paula Marie Ragan, Michael B. Atkins, James W. Mier, David McDermott
Abstract: Disclosed herein is a class of molecules termed remodilins that are effective in treating asthma, pulmonary fibrosis, and associated disorders. The molecules ameliorate asthma and pulmonary fibrosis symptoms by various mechanisms, including inhibiting airway smooth muscle contractile protein accumulation, reducing airway constrictor hyperresponsiveness, inhibiting bronchial fibroblast transformation into myofibroblasts, and/or treating or preventing airway or pulmonary fibrosis.
Type:
Application
Filed:
April 2, 2020
Publication date:
June 9, 2022
Applicants:
The University of Chicago, The United States of America,as Represented by the Secretary, Department of Health and Human Servic, President and Fellows of Harvard College, IIT Research Institute, Beth Israel Deaconess Medical Center, Inc.
Inventors:
Julian SOLWAY, Nickolai DULIN, Diane Luci, David MALONEY, Chan Young PARK, Jeffrey FREDBERG, David MCCORMICK, Ramaswamy KRISHNAN
Abstract: This disclosure relates to novel targets for angiogenic disorders. Novel oligonucleotides are also provided. Methods of using the novel oligonucleotides for the treatment of angiogenic disorders (e.g., preeclampsia) are also provided.
Type:
Grant
Filed:
November 6, 2019
Date of Patent:
May 31, 2022
Assignees:
UNIVERSITY OF MASSACHUSETTS, BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
Inventors:
Anastasia Khvorova, Melissa Moore, Anton A. Turanov, Ananth Karumanchi
Abstract: The invention provides compositions, methods, and kits for the treatment or prevention of viral infections. The polyvalent (e.g., 2-valent) vaccines described herein incorporate computationally-optimized viral polypeptides that can increase the diversity or breadth and depth of cellular immune response in vaccinated subjects.
Type:
Grant
Filed:
September 10, 2020
Date of Patent:
May 17, 2022
Assignees:
Beth Israel Deaconess Medical Center, Inc., Triad National Security, LLC
Inventors:
Dan H. Barouch, Bette T. Korber, William M. Fischer
Abstract: A pipetting device includes a housing, a valve assembly, and an actuator assembly. The housing includes a tip for receiving a capillary tube. The valve assembly includes a shuttle valve having a filling position and a dispensing position and a valve rod. The actuator assembly includes an actuator, a valve trigger, a piston mount, and an indexing mechanism. The actuator extends from the housing and has a push button coupled to a push rod. The valve trigger being configured to engage the valve assembly and includes an aperture configured to receive the piston mount therein. The indexing mechanism is configured to index a rotated position of the push button to a predefined volume of dispensed fluid.
Type:
Grant
Filed:
February 14, 2018
Date of Patent:
May 17, 2022
Assignees:
FRAUNHOFER USA, INC., CHILDREN'S MEDICAL CENTER CORPORATION, BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
Inventors:
Alexis Sauer-Budge, Holger Wirz, Samuel J. Brookfield, Nira Pollock, Ronald Janzen
Abstract: The present invention features methods of extracting amylase trypsin inhibitors (ATIs) from processed and unprocessed foodstuff, determining bioactivity of ATIs, quantifying the amount of ATIs in a foodstuff, and reducing the content of ATIs in a foodstuff.
Type:
Grant
Filed:
October 28, 2016
Date of Patent:
April 5, 2022
Assignee:
Beth Israel Deaconess Medical Center, Inc.
Abstract: The invention relates to the treatment and prevention of cancer by administering agents that inhibit the activity of microRNAs that modulate tumor suppressor genes, which can include PTEN, p53, and INPP4B, among others. Inhibitors can include oligonucleotides that are at least partially complementary to these miRNAs. In some embodiments, these inhibitors are chemically modified oligonucleotides, including locked nucleic acids (LNAs).
Type:
Grant
Filed:
October 6, 2017
Date of Patent:
March 15, 2022
Assignee:
BETH ISRAEL DEACONESS MEDICAL CENTER
Inventors:
Pier Paolo Pandolfi, Laura Poliseno, Yvonne Tay, Leonardo Salmena
Abstract: The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating and/or preventing proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.
Type:
Application
Filed:
May 4, 2021
Publication date:
February 24, 2022
Applicants:
Children's Medical Center Corporation, Beth Israel Deaconess Medical Center, Inc.
Abstract: Disclosed herein is a class of molecules termed remodilins that inhibit serum response factor (SRF). By inhibiting SRF, a number of downstream pathways can be targeted. The remodilins can be used to treat glaucoma, inhibit tumor cell growth, inhibit tumor metastasis, inhibit hypoxia-induced response, and/or reduce cellular metabolism.
Type:
Application
Filed:
April 2, 2020
Publication date:
February 10, 2022
Applicants:
The University of Chicago, The United States of America as Represented by the Secretary Department of Health and Human Services, President and Fellows of Harvard College, IIT Research Institute, Beth Israel Deaconess Medical Center, Inc.
Inventors:
Julian SOLWAY, Nickolai DULIN, Marsha ROSNER, Gokhan MUTLU, Diane LUCI, David MALONEY, Chan Young PARK, Jeffrey FREDBERG, David MCCORMICK, Ramaswamy KRISHNAN
Abstract: The invention features immunogenic compositions and vaccines containing an optimized human immunodeficiency virus (HIV) envelope (Env) polypeptide (e.g., a stabilized trimer of optimized HIV Env polypeptides) or a polynucleotide encoding an optimized HIV Env polypeptide and uses thereof. The invention also features methods of treating and/or preventing a HIV infection by administering an immunogenic composition or vaccine of the invention to a subject (e.g., a human).
Type:
Grant
Filed:
October 17, 2017
Date of Patent:
January 25, 2022
Assignees:
Beth Israel Deaconess Medical Center, Inc., Triad National Security, LLC
Inventors:
Dan H. Barouch, Christine Bricault, Bette T. Korber, Karina Yusim
Abstract: Stabilized trimers of a clade A strain and a clade C strain of HIV-1 are provided. Broadly neutralizing antisera against HIV-1, methods of making broadly neutralizing antisera against HIV-1, broadly neutralizing vaccines against HIV-1, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided.
Type:
Grant
Filed:
April 27, 2020
Date of Patent:
January 25, 2022
Assignees:
Beth Israel Deaconess Medical Center, Inc., Children's Medical Center Corporation
Inventors:
Stephen C. Harrison, Bing Chen, Dan Barouch, Joseph P. Nkolola, Michael Scott Seaman
Abstract: Compositions, vaccines and methods for inducing an immunity, including a protective immunity, against Human Immunodeficiency Virus (HIV) infection are described. Heterologous vaccine combinations of one or more adenovirus 26 vectors using for priming immunization and an isolated HIV antigenic polypeptide in combination with one or more MVA vectors for boosting immunization induced strong protective immunity against infections by one or multiple clades of HIV.
Type:
Grant
Filed:
October 4, 2019
Date of Patent:
December 28, 2021
Assignees:
Janssen Vaccines & Prevention B.V., Beth Israel Deaconess Medical Center, Inc.
Inventors:
Dan Barouch, Johanna Schuitemaker, Maria Grazia Pau, Danielle Van Manen, Frank Tomaka, Jennifer Anne Hendriks
Abstract: Described are N332 glycan-dependent antibodies for treating human immunodeficiency virus (HIV) in a subject that is infected with HIV and that is receiving antiretroviral therapy (ART).
Type:
Grant
Filed:
August 8, 2019
Date of Patent:
December 21, 2021
Assignee:
Beth Israel Deaconess Medical Center, Inc.
Abstract: Electrical impedance myography (EIM) can be used for assessment and diagnosis of muscular disorders. EIM includes applying an electrical signal to a region of tissue and measuring a resulting signal. A characteristic of the region of tissue is determined based on the measurement. Performing EIM at different frequencies and modeling one or more impedance metrics as a function of frequency may provide impedance model parameters that can aid in the assessment and diagnosis. Devices are described that facilitate assessment and diagnosis using EIM.
Type:
Application
Filed:
April 12, 2021
Publication date:
November 25, 2021
Applicant:
Beth Israel Deaconess Medical Center, Inc.
Inventors:
Seward B. Rutkove, Benjamin Sanchez Terrones
Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.
Type:
Application
Filed:
December 22, 2020
Publication date:
November 25, 2021
Applicants:
The Brigham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.
Inventors:
Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
Abstract: The invention provides, inter alia, fatty acyl hydroxy fatty acid (FAHFA; a novel class of estolide-related molecules) and diagnostic and treatment methods for a variety of disorders—including diabetes-related disorders, Metabolic Syndrome, polycyctic ovarian syndrome, cancer, and inflammatory disorders—using them; as well as methods of screening for additional compounds that are useful in treating these disorders and/or that modulate FAHFA levels, FAHFA-mediated signaling, and FAHFA-mediated biological effects.
Type:
Grant
Filed:
March 8, 2018
Date of Patent:
November 16, 2021
Assignees:
Beth Israel Deaconess Medical Center, Inc., President and Fellows of Harvard College
Inventors:
Barbara B. Kahn, Mark A. Herman, Alan Saghatelian, Edwin Homan, Mark M. Yore, Ismail Syed, Pedro M. M. Moraes Vieira
Abstract: Systems and methods for acquiring magnetic resonance imaging (MRI) images of a subject are provided. The method includes performing a pulse sequence to elicit spin echoes, wherein the pulse sequence includes a radio frequency (RF) excitation pulse and a series of RF refocusing pulses that refocus echoes with flip angles in the series of RF refocusing pulses that are varied. The method also includes scaling MRI data associated with each echo by a correction factor that is determined for each echo to create scaled MRI data and that is not the same for all echoes. The method then includes reconstructing an image of the subject using the scaled MRI data.
Type:
Grant
Filed:
March 22, 2018
Date of Patent:
November 2, 2021
Assignee:
BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
Abstract: Disclosed herein are compounds comprising an electrophilic moiety and rigid moiety for use in modulating an activity of Pin1. The rigid moiety comprises at least one functional group that is capable of forming hydrogen bonds with hydrogen atoms, wherein the electrophilic moiety and the rigid moiety are arranged such that the electrophilic moiety is capable of covalently binding to the Cys113 residue of Pin1, and the rigid moiety is capable of forming hydrogen bonds with the Gln131 and His 157 residues of Pin1. Further disclosed are novel compounds having Formula Id: wherein the dashed line, W, X, Y, Z, Ra-Rc, R1, R2, L1, L2 and n are as defined herein, and libraries comprising such compounds. Further disclosed are methods of identifying a compound capable of modulating an activity of Pin1, by screening a library of compounds.
Type:
Application
Filed:
July 8, 2021
Publication date:
October 28, 2021
Applicants:
Yeda Research and Development Co. Ltd., Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center, Inc.
Inventors:
Nir LONDON, Daniel ZAIDMAN, Christian DUBIELLA, Nathanael S. GRAY, Benika Joan PINCH, Kun Ping LU, Alfred Thomas LOOK, Shuning HE, Xiao Zhen ZHOU, Xiaolan LIAN
Abstract: Compositions and methods are disclosed herein for treating or reducing the symptoms of a renal disease, such as focal segmental glomerulosclerosis (FSGS), hypertensive end-stage kidney disease (ESKD), and HIV-associated nephropathy (a distinct form of FSGS, also termed collapsing glomerulopathy). The compositions include the common variant of APOL1 and fragments thereof, as well as antibodies and fragments thereof that bind and neutralize pathogenic APOL1, nucleic acid molecules that encode the common variant of APOL1 and fragments thereof, and other compounds that bind and neutralize pathogenic APOL1. The methods of the invention include administering one or more of the compositions of the invention to a subject having or at risk of developing renal disease.
Type:
Grant
Filed:
July 23, 2019
Date of Patent:
May 17, 2022
Assignee:
Beth Israel Deaconess Medical Center, Inc.